-
1
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Published 2025-03-01Subjects: Get full text
Article -
2
Reticulocyte hemoglobin content: a new frontier in iron deficiency diagnostics for major surgical patients
Published 2025-01-01Subjects: Get full text
Article -
3
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
Published 2025-01-01Subjects: Get full text
Article -
4
The frequency of mutations in advanced thyroid cancer in Japan: a single-center study
Published 2024-01-01Subjects: Get full text
Article -
5
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
Published 2025-01-01Subjects: Get full text
Article -
6
Applicability of a computer retinal model for scale-dependent investigation of legibility problems
Published 2025-02-01Subjects: Get full text
Article -
7
A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022
Published 2024-07-01Subjects: Get full text
Article -
8
Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer
Published 2025-01-01Subjects: “…RET fusion…”
Get full text
Article -
9
-
10
State-of-the-Art Review of Emerging Trends in Renewable Energy Generation Technologies
Published 2025-01-01Subjects: “…renewable energy technology (RET)…”
Get full text
Article -
11
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Published 2025-01-01Subjects: Get full text
Article -
12
-
13
Integration of Renewable Energy Technologies in Smart Building Design for Enhanced Energy Efficiency and Self-Sufficiency
Published 2023-11-01Subjects: “…Renewable Energy Technologies (RETs), Smart Buildings, Energy Efficiency, Self-Sufficiency, Integration.…”
Get full text
Article